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Vitamin D deficiency is associated with cardiovascular
disease, the most common cause of mortality in hemodialysis
patients. To investigate the relation between blood levels of
25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D
(1,25D) with hemodialysis outcomes, we measured baseline
vitamin D levels in a cross-sectional analysis of 825
consecutive patients from within a prospective cohort of
incident US hemodialysis patients. Of these patients, 78%
were considered vitamin D deficient with 18% considered
severely deficient. Calcium, phosphorus, and parathyroid
hormone levels correlated poorly with 25D and 1,25D
concentrations. To test the association between baseline
vitamin D levels and 90-day mortality, we selected the next
175 consecutive participants who died within 90 days and
compared them to the 750 patients who survived in a nested
case–control analysis. While low vitamin D levels were
associated with increased mortality, significant interaction
was noted between vitamin D levels, subsequent active
vitamin D therapy, and survival. Compared to patients with
the highest 25D or 1,25D levels who received therapy,
untreated deficient patients were at significantly increased
risk for early mortality. Our study shows that among incident
hemodialysis patients, vitamin D deficiency is common,
correlates poorly with other components of mineral
metabolism and is associated with increased early mortality.
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Vitamin D deficiency is common in hospitalized and
otherwise healthy individuals throughout the world.1–8
Maintaining adequate blood levels of 25-hydroxyvitamin D
(25D), the storage form of vitamin D, requires sufficient de
novo cutaneous synthesis stimulated by ultraviolet radiation
or adequate dietary intake of fortified foods and nutritional
supplements.9,10 The kidney converts 25D to its biologically
active hormonal form, 1,25-dihydroxyvitamin D (1,25D),
which binds nuclear receptors that regulate gene transcrip-
tion.11,12 Since the 17th century, clinicians have been familiar
with the consequences of severe vitamin D deficiency in the
form of rickets with its accompanying musculoskeletal and
biochemical abnormalities and its associated increased risk
for early death.2,13,14 In the current era, even with the
potential resurgence of rickets,14 severe vitamin D deficiency
is less common. Nevertheless, given the ubiquitous tissue
distribution of the vitamin D receptor, mild to moderate
vitamin D deficiency has been linked to diabetes, malignancy,
neurological disorders, hypertension, and congestive heart
failure in selected populations, although the results have been
inconsistent.15–22
Patients with kidney disease are at high risk for 25D
deficiency and, unlike non-kidney disease patients who are
able to tightly regulate 1,25D levels within the normal range,
they also demonstrate profound reductions in 1,25D
levels.23–27 Following the initiation of dialysis, patients with
kidney disease are at dramatically increased risk of early
mortality.28 The combination of significant 25D deficiency,
impaired conversion of 25D to 1,25D, and high early
mortality rates render dialysis patients the ideal model to
study the impact of vitamin D deficiency on mortality in the
current era. Few, if any, studies have examined the potential
link between vitamin D deficiency and mortality on
hemodialysis. We and others have reported that therapy
with activated vitamin D is independently associated with
improved survival among patients initiating hemodialy-
sis.29–34 Although these observational studies are subject to
bias and confounding, they suggest that decreased endogen-
ous vitamin D levels may be linked to increased mortality. We
therefore examined the prevalence of vitamin D deficiency in
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a cross-section of US patients at the time they initiated
chronic hemodialysis and, in a case–control sample of
patients nested within a prospective cohort, tested the
hypothesis that decreased levels of 25D and 1,25D before
treatment with any active vitamin D are associated with
increased risk for early mortality.
RESULTS
Demographics and circulating 25D and 1,25D levels
The initial cross-sectional study sample included 825
consecutive patients from 569 unique hemodialysis centers
in 37 states. Their baseline characteristics at the initiation of
dialysis are presented in Table 1. Distributions of 25D and
1,25D levels are shown in Figure 1. The mean level of 25D
was 21713 ng/ml. Only 22% of subjects had 25D levels
430 ng/ml, whereas 60% had levels between 10 and 30 ng/
ml; the remaining 18% were severely vitamin D deficient
(o10 ng/ml). Compared with men, women were more likely
to be severely 25D deficient (23 vs 15%; Po0.01). Compared
with white subjects, black subjects had significantly lower
mean 25D levels (17710 vs 24714 ng/ml; Po0.01) and were
more likely to be severely 25D deficient (31 vs 12%; Po0.01).
Compared to patients without diabetes, those with diabetes
were more likely to be severely 25D deficient (22 vs 17%;
Po0.01). The mean level of 1,25D was 11710 pg/ml. Serum
1,25D levels did not differ between men and women, white
and black subjects, or between patients with and without
diabetes. As expected, both 25D and 1,25D levels were
significantly greater among patients who initiated dialysis in
the summer compared with those who initiated in the winter
(25D: 25714 vs 19711 ng/ml; Po0.01; 1,25D: 13711 vs
1079 pg/ml; Po0.01).
25D levels correlated weakly with serum levels of calcium
(r¼ 0.18), parathyroid hormone (PTH) (r¼0.14), and
albumin (r¼ 0.31); there was no correlation with serum
phosphorus or creatinine. Table 2a illustrates mineral and
nutrition metabolites according to the 25D groups. Subjects
with vitamin D deficiency had slightly lower serum calcium
and albumin levels, and increased PTH and alkaline
phosphatase levels compared to subjects with normal 25DTable 1 | Baseline characteristics of the initial 825 consecutive
study participants
Demographic characteristics
Age (years) 63715
Gender (% women) 47
Race (%)
White 60
Black 32
Other 8
Etiology of renal failure (%)
Diabetes mellitus 43
Hypertension 34
Glomerulonephritis 10
Polycystic kidney disease 3
Other 10
Mean arterial pressure (mm Hg) 98716
Body mass index (kg/m2) 27.376.8
Access at the initiation of hemodialysis (%)
Arteriovenous fistula 27
Arteriovenous graft 12
Catheter 61
Comorbid conditions (%)
Coronary artery disease/myocardial infarction 16
Congestive heart failure 21
Peripheral vascular disease 10
Stroke 4
Hyperlipidemia 18
Malignancy 4
Chronic obstructive pulmonary disease 4
Baseline laboratory test results
Calcium (mg/dl) 8.570.8
Phosphorus (mg/dl) 4.671.6
Parathyroid hormone (bio-intact; pg/ml) 193 (105, 341)
Albumin (g/dl) 3.570.5
Creatinine (mg/dl) 6.372.7
Hemoglobin (g/l) 10.371.4
Results are expressed as mean7s.d. or medians (interquartile ranges) as
appropriate.
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Figure 1 | Distribution of vitamin D levels among 825
incident hemodialysis patients. (a) 25-hydroxyvitamin D and
(b) 1,25-dihydroxyvitamin D (25D). The vertical dashed line (a)
indicates the lower limit of the normal range for 25D of 30 ng/ml.
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stores. Nevertheless, 79% of patients with serum PTH
o150 pg/ml were vitamin D deficient with 25D levels
o30 ng/ml.
The strongest correlate of 1,25D levels was the serum 25D
(r¼ 0.31). Other factors that correlated with 1,25D included
serum calcium (r¼ 0.12) and albumin (r¼ 0.21); there was
no correlation with PTH, phosphorus, or creatinine levels.
Table 2b illustrates mineral and nutrition metabolites
according to tertiles of serum 1,25D. Compared to subjects
in the upper 1,25D tertile, those in the lower tertiles had
decreased serum calcium and albumin levels. There was no
association between 1,25D tertiles and serum phosphorus,
PTH, alkaline phosphatase, or creatinine.
The median PTH was 193 pg/ml; 17% had PTH levels
o75 pg/ml, 20% were 75–150 pg/ml, and 63% were4150 pg/
ml. Compared to subjects with PTH4150 pg/ml, those with
levels p150 pg/ml had no significant difference in median
1,25D levels (12711 vs 11710; P¼ 0.9) but significantly
increased mean 25D levels (24712 vs 20713; Po0.01).
Nonetheless, there was substantial overlap in the distribu-
tions of 25D and 1,25D levels according to baseline PTH
levels as shown in Figure 2a and b.
Circulating 25D, 1,25D, and survival on hemodialysis
The case–control sample of 1000 patients was used to study
survival. Baseline characteristics according to 90-day out-
comes are presented in Table 3. Factors that were associated
with early mortality in this study were similar to those
reported in larger populations initiating hemodialysis in the
United States.35 In the crude analyses, there were no
significant differences in mean levels of 25D (21712 vs
21713 ng/ml; P¼ 0.50) or 1,25D (1078 vs 11710 pg/ml;
P¼ 0.12) comparing subjects who died with those who
survived. However, subjects with severe 25D deficiency
(o10 ng/ml) were at significantly increased risk of all-cause
mortality compared to subjects with normal 25D levels
Table 2a | Markers of mineral metabolism, nutrition, and renal function according to serum 25D levels
Severely deficient o10 ng/ml n=147 Deficient 10–30 ng/ml n=472 Replete 430 ng/ml n=173 P-values
Calcium (mg/dl) 8.370.8 8.470.8 8.770.8 o0.01
Phosphorus (mg/dl) 4.771.6 4.671.5 4.771.6 NS
PTH (pg/ml) 250 (139, 386) 195 (105, 343) 159 (81, 258) o0.01
Alkaline phosphatase (U/l) 92 (70, 124) 83 (65, 112) 84 (66, 107) 0.03
Albumin (g/dl) 3.270.6 3.570.5 3.770.5 o0.01
Creatinine (mg/dl) 6.272.4 6.372.7 6.272.9 NS
25D, 25-hydroxyvitamin D; NS, nonsignificant; PTH, parathyroid hormone.
Results are expressed as mean7s.d. or medians (interquartile ranges) as appropriate.
Table 2b | Markers of mineral metabolism, nutrition, and renal function according to serum 1,25D levels
Tertile 1 o6 pg/ml n=184 Tertile 2 6–13 pg/ml n=234 Tertile 3 413 pg/ml n=188 P-values
Calcium (mg/dl) 8.370.9 8.570.8 8.670.8 o0.01
Phosphorus (mg/dl) 4.871.7 4.671.6 4.671.5 NS
PTH (pg/ml) 183 (103, 300) 207 (112, 377) 181 (91, 301) NS
Alkaline phosphatase (U/l) 86 (62, 114) 84 (67, 116) 83 (67, 109) NS
Albumin (g/dl) 3.370.6 3.570.5 3.670.4 o0.01
Creatinine (mg/dl) 6.572.8 6.072.5 6.173.0 NS
1,25D, 1,25-dihydroxyvitamin D; NS, nonsignificant; PTH, parathyroid hormone.
Results are expressed as mean7s.d. or medians (interquartile ranges) as appropriate.
0
20
40
<55
55−85
86−125
126−160
161−190
191−240
241−290
291−385
386−550
>550
25
-h
yd
ro
xy
vit
am
in
 D
 (n
g/
m
l)
Parathyroid hormone (pg/ml)
<55
55−85
86−125
126−160
161−190
191−240
241−290
291−385
386−550
>550
Parathyroid hormone (pg/ml)
0
20
40
1,
25
-d
ih
dr
ox
yv
ita
m
in
 D
 (p
g/
m
l)
Figure 2 | Distributions of vitamin D levels according to
baseline PTH levels. (a) 25-hydroxyvitamin D (n¼ 792) and
(b) 1,25-dihydroxyvitamin D (n¼ 606). PTH levels are divided into
groups according to the ascending 10th percentiles of the
distribution in the entire study population. Mean vitamin D levels are
represented by the central point and the bars represent interquartile
ranges (25th and 75th percentiles).
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(Table 4a). There was a statistically significant increased risk
of early mortality in subjects with 1,25D levels of 6–13
compared with 413 pg/ml but no significant increased risk
in the o6 pg/ml group (Table 4b).
There was no significant interaction between PTH,
vitamin D levels, and survival, modeling PTH either on a
continuous scale or categorically as por 4150 pg/ml.
Compared to no treatment, subsequent therapy with
activated vitamin D was associated with a multivariate-
adjusted survival advantage (odds ratio (OR) 0.60; 95%
confidence interval (CI) 0.37, 0.91; Po0.01). Given the effect
of active vitamin D therapy on outcome, we formally tested
for and identified effect modification between active vitamin
D therapy, endogenous vitamin D levels, and survival
Table 3 | Baseline characteristics of patients who survived or died within the first 90 days of initiating hemodialysis
Survived n=750 Died n=250 P-values
Demographic characteristics
Age (years) 62716 71713 o0.01
Gender (% women) 47 46 NS
Race (%) o0.01
White 59 72
Black 33 24
Other 8 4
Etiology of renal failure (%) NS
Diabetes mellitus 43 43
Hypertension 34 37
Glomerulonephritis 10 6
Polycystic kidney disease 3 1
Other 10 13
Mean arterial pressure (mm Hg) 99715 89722 o0.01
Body mass index (kg/m2) 27.376.7 27.077.5 NS
Access at the initiation of hemodialysis (%) o0.01
Arteriovenous fistula 28 9
Arteriovenous graft 13 7
Catheter 59 84
Comorbid conditions (%)
Coronary artery disease/myocardial infarction 16 18 NS
Congestive heart failure 19 30 o0.01
Peripheral vascular disease 10 12 NS
Stroke 4 7 0.01
Hyperlipidemia 18 12 0.01
Malignancy 4 8 0.01
Chronic obstructive pulmonary disease 4 5 NS
Baseline laboratory test results
Calcium (mg/dl) 8.570.8 8.470.8 NS
Phosphorus (mg/dl) 4.771.6 4.370.9 o0.01
Parathyroid hormone (intact; pg/ml) 199 (111, 341) 166 (92, 297) o0.01
Albumin (g/dl) 3.570.5 3.270.6 o0.01
Creatinine (mg/dl) 6.372.7 5.372.3 o0.01
Hemoglobin (g/l) 10.371.4 10.471.3 NS
NS, nonsignificant.
Results are expressed as mean7s.d. or medians (interquartile ranges) as appropriate.
Table 4a | ORs of risk of death within 90 days of initiating chronic hemodialysis according to baseline 25D levels
25D o10 ng/ml n=187 10–30 ng/ml n=594 430 ng/ml n=203
All-cause mortality
Age, gender, race-adjusted 1.9* (1.3–2.9) 1.4* (1.0–2.0) 1.0 (REF)
Multivariate-adjusted 1.6* (1.0–2.4) 1.3 (0.9–1.8) 1.0 (REF)
Cardiovascular mortality
Age, gender, race-adjusted 1.9* (1.0–3.4) 1.8* (1.2–2.9) 1.0 (REF)
Multivariate-adjusted 1.6 (0.8–3.0) 1.6* (1.0–2.6) 1.0 (REF)
25D, 25-hydroxyvitamin D; OR, odds ratio.
*Po0.05 compared with the reference group.
REF refers to the reference group for these analyses.
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(Po0.01 for 25D active vitamin D; P¼ 0.01 for
1,25D active vitamin D). Therefore, additional analyses
were performed with vitamin D levels, and active vitamin D
treatment interaction categories included in the model.
Figure 3 illustrates the risk of all-cause and cardiovascular
mortality within the groups categorized by vitamin D levels
and active vitamin D therapy (summarized as Tþ , received
therapy or T, untreated). In these multivariate-adjusted
analyses, the reference groups were Tþ subjects in the
highest vitamin D groups (25D 430 ng/ml; 1,25D 413 pg/ml).
Other covariates included in the multivariate models
included age, sex, race, etiology of real failure, standardized
mortality rates, blood pressure, vascular access, albumin,
creatinine, PTH, calcium, phosphorus, hemoglobin, and a
past medical history of coronary artery disease, stroke,
malignancy, or congestive heart failure. Compared to the 25D
referent group, there was a monotonic increase in risk of all-
cause mortality among T subjects with decreasing 25D
Table 4b | ORs of risk of death within 90 days of initiating chronic hemodialysis according to baseline 1,25D levels
1,25D o6 pg/ml n=220 6–13 pg/ml n=253 413 pg/ml n=246
All-cause mortality
Age, gender, race-adjusted 1.5 (0.9–2.4) 1.7* (1.1–2.7) 1.0 (REF)
Multivariate-adjusted 1.4 (0.8–2.3) 1.8* (1.1–2.9) 1.0 (REF)
Cardiovascular mortality
Age, gender, race-adjusted 1.6 (0.9–2.8) 1.6 (0.9–2.8) 1.0 (REF)
Multivariate-adjusted 1.5 (0.8–2.9) 1.8 (0.9–3.4) 1.0 (REF)
1,25D, 1,25-dihydroxyvitamin D; OR, odds ratio.
*Po0.05 compared with the reference group.
REF refers to the reference group for these analyses.
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Figure 3 | Multivariate-adjusted ORs of 90-day all-cause and cardiovascular (CV) mortality on hemodialysis according to vitamin D
levels and whether or not patients received treatment with active vitamin D. (a) 25-hydroxyvitamin D and all-cause mortality;
(b) 25-hydroxyvitamin D and CV mortality; (c) 1,25-dihydroxyvitamin D and all-cause mortality; (d) 1,25-dihydroxyvitamin D and CV
mortality. The reference groups (R) were subjects who were treated with active vitamin D and had 25-hydroxyvitamin D levels X30 ng/ml
or 1,25-dihydroxyvitamin D levels X13 pg/ml. N¼ 984 for 25-hydroxyvitamin D analyses and 719 for 1,25-dihydroxyvitamin D analyses;
*Po0.05 for the comparison of the individual vitamin D level—vitamin D treatment groups with the corresponding referent groups.
1008 Kidney International (2007) 72, 1004–1013
o r i g i n a l a r t i c l e M Wolf et al.: Vitamin D levels and dialysis mortality
levels (Figure 3a): baseline 25D levels 430 ng/ml (OR 2.3;
95% CI 1.1, 5.1), 10–30 ng/ml (OR 2.5; 95% CI 1.3, 5.0), and
o10 ng/ml (OR 5.9; 95% CI 2.6, 13.7). The association
between decreasing 25D levels and increased risk among T
subjects increased when restricted to cardiovascular mortality
(Figure 3b): 25D levels 430 ng/ml (OR 4.8; 95% CI 1.5,
15.0), 10–30 ng/ml (OR 5.3; 95% CI 1.8, 15.4), and o10 ng/
ml (OR 8.3; 95% CI 2.4, 28.7). Although the effect size was
not monotonic and less strong compared to the 25D analyses,
T patients with 1,25D levels 6–13 pg/ml (OR 4.1; 95% CI
2.0, 8.2) ando6 pg/ml (OR 2.1; 95% CI 1.0, 4.6) were also at
significantly increased risk of early all-cause mortality
compared to the 1,25D referent group (Figure 3c); T
patients with 1,25D levels between 6 and 13 pg/ml (OR 4.5;
95% CI 1.9, 10.4) were at significantly increased risk of early
cardiovascular mortality (Figure 3d). In all of these analyses,
there was no increase in risk of mortality according to 25D or
1,25D levels in the subjects who subsequently received active
vitamin D therapy (Figure 3a–d).
In stratified analyses by vitamin D therapy, there was no
association between 25D, 1,25D, and all-cause mortality
among subjects subsequently treated with active vitamin D.
In an analysis of 25D restricted to T subjects (n¼ 324) and
parsimoniously adjusted for age, sex, PTH, and albumin, the
OR of all-cause mortality was 1.0 (95% CI 0.6, 1.8; P¼ 0.9)
for 25D levels of 10–30 ng/ml and 2.2 (95% CI 1.0, 5.1;
P¼ 0.05) for 25D levels o10 ng/ml compared with 25D
levels 430 ng/ml. In a similar stratified model of 1,25D
(n¼ 237), the adjusted OR of all-cause mortality was 3.1
(95% CI 1.5, 6.4; Po0.01) for 1,25D levels of 6–13 pg/ml and
1.5 (95% CI 0.7, 3.3; P¼ 0.3) for 1,25D levels o6 pg/ml
compared with 1,25D levels 413 pg/ml.
DISCUSSION
Incident hemodialysis patients living throughout the United
States are profoundly deficient in both 25D and 1,25D.
Although serum levels of calcium, phosphorus, and PTH are
biologically linked with vitamin D metabolism and are
traditionally used to identify vitamin D deficiency,10 these
parameters correlated poorly with vitamin D levels. Lower
serum levels of both 25D and 1,25D were associated with
increased mortality within 90 days of initiating hemodialysis,
a finding that was independent of standard nutritional
factors, residual renal function, comorbidities, other known
predictors of mortality on dialysis, and importantly,
biomarkers of mineral metabolism. To our knowledge, this
is the largest study of incident hemodialysis patients
throughout the United States to examine 25D and 1,25D
levels, and to determine the relationships between these
levels, traditional biomarkers of mineral metabolism, and
mortality.
The prevalence of vitamin D deficiency ranges between 20
and 50% in the general population.2,4,10 This high variability
likely reflects differences in the racial distribution and
sunlight exposure in the populations that were studied,
along with their prevalence of obesity, diabetes, advanced age,
nephrotic syndrome, and malabsorption, all risk factors for
vitamin D deficiency. Differences in laboratory measures may
have also contributed to the variability. In this study in which
all samples were tested in a single laboratory and during the
same time period, 78% of new hemodialysis patients were
vitamin D deficient. Although this high prevalence may relate
in part to the large representation of black and diabetic
subjects, which is typical of US dialysis populations, these
factors are unlikely to fully account for the pervasiveness and
severity of 25D deficiency we observed. While this is
especially noteworthy, as 25D is synthesized by the liver
and does not depend on normal renal function,36 the
cutaneous production of cholecalciferol, the precursor of
25D, is impaired in uremia.37 In contrast, circulating 1,25D
levels largely depend on the ability of the kidney’s 1a-
hydroxylase to convert 25D to 1,25D. Severe 1,25D deficiency
in patients with renal failure is often assumed, but this is the
first study to document it in a large incident hemodialysis
cohort and to demonstrate its association with mortality.
It is interesting that the magnitude of risk of mortality was
significantly greater for decreased 25D levels than decreased
1,25D levels. This may reflect preferable characteristics of
25D as a biomarker compared with 1,25D, including its more
reproducible assay, longer half-life and thus more accurate
measure of exposure over time, and lack of regulation within
a narrow range.2 Differences in the reference groups may also
explain the discrepancy. The reference group for the 25D
analyses was made up of patients with normal levels against
whom deficient patients were compared, whereas the
reference group for the 1,25D analyses included mostly
patients with severely reduced 1,25D levels. In addition to
these study design issues, it is also possible that 25D has
important biological effects, such as on the cardiovascular
system, even in dialysis patients.38 Although 1,25D has
greater affinity for the vitamin D receptor, many cells also
express 1a-hydroxylase, including vascular smooth muscle
and endothelial cells.39–41 1,25D synthesized from circulating
25D in these cells can bind local receptors in autocrine/
paracrine pathways. Importantly, 25D circulates at B1000-
fold higher concentrations than 1,25D, suggesting that
maintaining adequate 25D stores may also be necessary,
especially for cells that rely on autocrine pathways.
Although previous observational studies suggest a sig-
nificant survival advantage associated with activated vitamin
D therapy,29–32,34 selection bias and residual confounding
may have contributed to the results. A critical strength of this
study is that clinicians did not have baseline 25D or 1,25D
levels to influence their management decisions. Therefore,
even if ‘healthier’ patients were more likely to be selected for
treatment with active vitamin D, such an argument cannot
explain the observation that lower levels of 25D and 1,25D
were associated with an increased risk for early mortality,
specifically among the patients who never received active
vitamin D therapy. It is possible that the sickest patients had
the lowest vitamin D levels, and that the increased mortality
risk was due to antecedent illness rather than vitamin D
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deficiency itself. Nevertheless, the graded effect we observed
was independent of comorbidities and other indicators of
overall health such as albumin and creatinine levels.
Furthermore, uncovering a statistically significant interaction
between endogenous vitamin D levels, subsequent vitamin D
therapy, and survival—namely, an increased risk of death
specifically among those deficient patients who were not
subsequently treated with active vitamin D—lends further
biological support to the significance of low vitamin D levels.
It must be emphasized, however, that only a randomized
controlled trial could provide definitive proof of a benefit of
treating vitamin D-deficient dialysis patients with vitamin D,
activated vitamin D, or both.
Vitamin D measurements are not part of routine dialysis
management, and only recently they have been recom-
mended in predialysis kidney disease patients.42 Even in the
latter group, however, the decision to measure 25D is often
linked to management of secondary hyperparathyroidism,
which is but one of several important biological targets for
vitamin D. Non-dialysis patients demonstrate a strong
inverse relationship between 25D levels below B30 ng/ml
and PTH,1,10 and small dialysis studies have also reported an
inverse relationship between PTH and 25D levels, with
correlations ranging from 0.23 to 0.32.25,43–45 In this
study of nearly 1000 patients from throughout the United
States, blood levels of PTH were a poor surrogate of 25D or
1,25D levels. Indeed, almost 80% of patients with serum PTH
levels o150 pg/ml were nonetheless vitamin D deficient.
Thus, relying on PTH to define whom to treat, rather than
directly measuring vitamin D levels, precludes the possibility
of identifying vitamin D deficiency in many patients who
may be at dramatically increased risk for early mortality.
Although these results suggest that perhaps patients with
kidney disease should be screened for vitamin D deficiency,
we cannot recommend routine measurements of vitamin D
levels in the clinical management of dialysis patients as a
result of this single study. We must exercise caution because
only a placebo-controlled, randomized trial of therapy could
prove a causal relationship between vitamin D levels, therapy,
and survival. Indeed, the nephrology literature is replete with
examples where strong epidemiological data support an
increased mortality risk associated with a deficiency (or
excess) of a biomarker, yet direct interventions to correct the
abnormality did not alter outcomes when tested in a
randomized trial.46–48 In addition, the relatively short
follow-up of incident patients we studied limits our ability
to generalize the results to prevalent patients over longer
durations of follow-up and increases the possibility of
confounding by comorbidities present before initiation of
dialysis. Although we adjusted for differences in comorbid-
ities, residual confounding remains a limitation. Therefore,
our results must be verified by other investigators in different
cohorts. If the results were consistent, future interventional
studies could be justified, particularly among patients who
initiate hemodialysis with PTH levels below the current
threshold for initiating vitamin D therapy.
MATERIALS AND METHODS
Accelerated Mortality on Renal Replacement (ArMORR) is a
nationally representative prospective cohort study of patients who
initiate chronic hemodialysis at any one of 41000 US dialysis
centers operated by Fresenius Medical Care, North America.
ArMORR contains detailed demographic and clinical data, includ-
ing comorbidities, laboratory results, and blood samples at dialysis
initiation and every 90 days thereafter to 1 year. Clinical data,
including results of laboratory tests and records of drug adminis-
tration, are collected prospectively and entered uniformly into a
central database by practitioners at the point of care. All clinical data
points arriving at Fresenius undergo rigorous quality assurance/
quality control (QA/QC) auditing because these data are directly
linked to Medicare billing services, and routine QA/QC measures are
mandated by the Clinical Quality Group and Data Entry Error
Reduction Task Force at Fresenius.32,33 All blood samples collected
for clinical care are uniformly shipped to and processed by Spectra
East (Rockland, NJ, USA), a good clinical practice (GCP)-accredited
central laboratory. After processing for routine clinical testing,
residual samples are shipped on ice to the ArMORR investigators
where the samples are aliquoted and stored in liquid nitrogen tanks.
This study was approved by the Institutional Review Board of the
Massachusetts General Hospital, which waived the need for
informed consent.
Study population
Between 1 July 2004 and 30 June 2005, 10 044 incident hemodialysis
patients representing 1056 US dialysis units were prospectively
enrolled into ArMORR. Of these 10 044 patients, 19 (0.2%) had
levels of either 25D or 1,25D measured for routine clinical purposes
within 90 days of initiating hemodialysis, whereas virtually all
patients had repeated measurements of calcium, phosphorus, and
PTH during the same period.
For this study, we excluded subjects who had initiated therapy
with oral or injectable vitamin D therapy before the collection of
their baseline blood sample. The first 825 consecutive patients
who enrolled in ArMORR and met these inclusion criteria were used
to study the distribution of baseline vitamin D levels and their
association with other markers of mineral metabolism in a
representative incident hemodialysis cohort. Of these 825 subjects,
75 (9%) died within 90 days of initiating dialysis and 750
survived for at least 90 days. To efficiently study the effects of 25D
and 1,25D levels on survival, we performed a nested case–control
study defining cases as subjects who died within 90 days of
initiating dialysis and controls as those who survived for at least 90
days. To increase power, we added the next 175 consecutive
ArMORR participants who died within 90 days of initiating dialysis
(n¼ 250 total cases) to the original sample to create a case–control
sample of 1:3 ratio with a total of 1000 subjects. All cases were
members of the 10 044 subjects recruited for ArMORR between 1
July 2004 and 30 June 2005; no additional subjects were recruited for
this study after the year of ArMORR enrollment. With a case–control
sample of 1000 and a 1:3 ratio, we had 490% power to detect an
OR of 2 among patients with vitamin D deficiency compared to
those with normal levels. Of the 1000 subjects, 984 had adequate
serum samples for 25D assays (244 cases and 740 controls), and 703
had adequate samples for 1,25D assays (183 cases and 527 controls).
There were no significant differences in demographic or baseline
laboratory characteristics among those with inadequate samples
compared with those who had sufficient sample volume for both
assays.
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Exposures, outcomes, and covariates
The primary exposures were baseline circulating levels of 25D and
1,25D that were collected within 14 days of initiating hemodialysis
and before starting any oral or injectable vitamin D. After collection,
blood samples were frozen in liquid nitrogen and underwent a single
thaw for this study following an average storage time of 8 months.
Given the number of samples to be tested, 25D and 1,25D levels
were measured in duplicate using commercially available radio-
immunoassay techniques (DiaSorin Inc., Stillwater, MN, USA).49–52
The coefficients of variation (CVs) for 25D measurements were
o3% at levels o30 ng/ml and for 1,25D the CVs were o6.5% at
levels o32.5 pg/ml. Based on clinical definitions2,36 and for
purposes of interpretability, 25D levels X30 ng/ml were considered
replete, whereas vitamin D deficiency was defined as a levelo30 ng/ml
and severe deficiency as levels o10 ng/ml. As cut points for 1,25D
levels are less well defined, we analyzed tertiles of 1,25D levels
according to its distribution in the overall population. Blood levels
of PTH were measured using the Nichols Advantage Bio-Intact PTH
assay that detects bioactive (1–84) hormone.
The primary outcome was all-cause mortality within 90 days after
initiating dialysis, and the secondary outcome was cardiovascular
mortality. Ninety-day mortality was chosen as the primary end point
for several reasons. The rate of early mortality on hemodialysis is
almost double that seen after the first 90 days,53 yet risk factors for
early mortality have been mostly understudied. In addition, outcome
events during this time period are proximate to the primary exposure
and thus are affected less by co-interventions and other potential
confounders. Finally, active vitamin D use increases over time on
hemodialysis, a phenomenon that would limit the statistical power of
analyses of the effects on survival of vitamin D levels among untreated
patients. Death was confirmed by mandatory discharge diagnosis
reports from dialysis centers, and cardiovascular deaths were
determined based on International Classification of Diseases (ICD)-9
mortality codes, despite their limitations, as done previously.32,33
We analyzed several covariates including age, gender, race, etiology
of renal failure, blood pressure, body mass index, dialysis access at
initiation (arteriovenous fistula, graft, or venovenous catheter),
dialysis dose assessed by the urea reduction ratio, facility-specific
standardized mortality rates,54 and comorbidities at the initiation of
dialysis (diabetes, hypertension, coronary artery disease, myocardial
infarction, peripheral vascular disease, stroke, congestive heart failure,
chronic obstructive pulmonary disease, non-cutaneous malignancy,
and liver disease). Comorbidities were ascertained by the individual
patients’ practitioners and derived from the initial intake history,
physical examination, and medical records such as referrals and
discharge summaries. To further capture overall health status, we also
examined whether patients initiated hemodialysis as an outpatient vs
in the hospital. Finally, we analyzed the first results of laboratory tests
obtained at the initiation of dialysis including sodium, potassium,
bicarbonate, blood urea nitrogen, creatinine, calcium, phosphorus,
PTH, alkaline phosphatase, albumin, and hemoglobin.
Analysis
We used two-sample t-tests and Fisher’s exact test to compare
demographic and laboratory characteristics and vitamin D levels at
the initiation of dialysis among the patients who died and the 750
patients who survived. To examine whether routine laboratory tests
of mineral metabolism were associated with decreased vitamin D
levels, we used Spearman correlation coefficients to summarize the
correlations between vitamin D levels and biomarkers of mineral
metabolism. We used linear regression models to examine trends in
mean levels of mineral metabolites across the vitamin D groups.55 In
addition, as PTH is currently the clinical standard of care used to
define when to administer active vitamin D treatment, we examined
the range of 25D and 1,25D levels across the spectrum of PTH
measurements and tested differences in vitamin D levels according
to PTH levels por 4150 pg/ml.
We used logistic regression analyses on the case–control sample
of 1000 patients to examine survival on hemodialysis according to
baseline vitamin D levels. We performed separate analyses for 25D
and 1,25D, examining them as continuous and also as categorical
exposures using the cut points described above to test for potential
nonlinear associations. Although we excluded subjects who received
vitamin D therapy before the measurement of their vitamin D levels
to limit misclassification of exposure, 62% of subjects subsequently
initiated therapy with active vitamin D during the follow-up period,
which is consistent with national data.29,32 In active vitamin
D-treated subjects, therapy began at a median of 14 days after initiation
of dialysis and continued for a median duration of 74 days.
Independent predictors of subsequent therapy with active vitamin D
included baseline PTH (higher levels associated with therapy) and
phosphorus levels (lower levels associated with therapy). As
exogenous vitamin D therapy could offset risk associated with
decreased endogenous vitamin D levels, we tested for interaction55
between vitamin D levels and survival by active vitamin D therapy
using w2 tests derived from logistic regression models. When
significant (Po0.05) interaction was detected, we analyzed multi-
variate-adjusted logistic regression models with interaction terms
(3 levels of 25D and 1,25D active vitamin D treatment status) and
models stratified by vitamin D therapy. We also tested for
interaction between vitamin D levels and PTH.
Multivariate logistic regression models were used to adjust for
potential confounders. We included covariates in the multivariate
models that have been associated with mortality on dialysis in
previous studies and those that were significantly different among
cases and controls in this study. Data points on individual covariates
were missing ino5% of subjects; for the multivariate analyses, these
covariates were treated as categorical variables with an additional
category for missing values. Otherwise, continuous variables were
analyzed on a continuous scale. PTH was also examined as a binary
variable (p or 4150 pg/ml).
As vitamin D levels are influenced by climate and season, we also
adjusted for the season (summer: 1 April to 30 September vs winter:
1 October to 31 March) and the states (divided into four groups
according to latitude) in which patients initiated dialysis, as
performed in previous vitamin D studies.2,10,56 Finally, we measured
vitamin D-binding protein, the primary binding protein for
circulating vitamin D, in a randomly selected subset of 100 cases
and 200 controls using an automated immunonephelometric
method (Dade Behring BNII, Marburg, Germany) with CVso7%,
which permitted analyses of the association between levels of
vitamin D and mortality independent of its carrier protein.
Adjusting models for vitamin D-binding protein levels, coding for
missing values, did not alter the results (data not shown). All results
are reported as mean7s.d. Analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC, USA).
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